137 related articles for article (PubMed ID: 2445485)
1. Selective cytotoxicity against tumor cells by cisplatin complexed to antitumor antibodies via carboxymethyl dextran.
Schechter B; Pauzner R; Arnon R; Haimovich J; Wilchek M
Cancer Immunol Immunother; 1987; 25(3):225-30. PubMed ID: 2445485
[TBL] [Abstract][Full Text] [Related]
2. Cis-platinum (II) complexes of carboxymethyl-dextran as potential antitumor agents. II. In vitro and in vivo activity.
Schechter B; Pauzner R; Wilchek M; Arnon R
Cancer Biochem Biophys; 1986 Oct; 8(4):289-98. PubMed ID: 2433022
[TBL] [Abstract][Full Text] [Related]
3. Cis-platinum(II) complexes of carboxymethyl-dextran as potential antitumor agents. I. Preparation and characterization.
Schechter B; Pauzner R; Arnon R; Wilchek M
Cancer Biochem Biophys; 1986 Oct; 8(4):277-87. PubMed ID: 2433021
[TBL] [Abstract][Full Text] [Related]
4. Blood levels and serum protein binding of cis-platinum(II) complexed to carboxymethyl-dextran.
Schechter B; Rosing MA; Wilchek M; Arnon R
Cancer Chemother Pharmacol; 1989; 24(3):161-6. PubMed ID: 2472228
[TBL] [Abstract][Full Text] [Related]
5. Molecules recognized by anti-idiotypic monoclonal antibodies to the B cell lymphoma, BCL1.
Tamura GS; McGrath MS; Weissman IL
J Mol Cell Immunol; 1987; 3(4):243-53. PubMed ID: 3509925
[TBL] [Abstract][Full Text] [Related]
6. Site-directed chemotherapy with a drug bound to anti-idiotypic antibody to a lymphoma cell-surface IgM.
Hurwitz E; Kashi R; Burowsky D; Arnon R; Haimovich J
Int J Cancer; 1983 Jun; 31(6):745-8. PubMed ID: 6862683
[TBL] [Abstract][Full Text] [Related]
7. Indirect immunotargeting of cis-Pt to human epidermoid carcinoma KB using the avidin-biotin system.
Schechter B; Arnon R; Wilchek M; Schlessinger J; Hurwitz E; Aboud-Pirak E; Sela M
Int J Cancer; 1991 May; 48(2):167-72. PubMed ID: 1708362
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of a murine B cell tumor with antibodies and F(ab')2 fragments against idiotypic determinants of its cell surface IgM.
Perek Y; Hurwitz E; Burowski D; Haimovich J
J Immunol; 1983 Sep; 131(3):1600-3. PubMed ID: 6604103
[TBL] [Abstract][Full Text] [Related]
9. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859
[TBL] [Abstract][Full Text] [Related]
10. A synergistic effect between anti-idiotype antibodies and anti-neoplastic drugs in the therapy of a murine B-cell tumor.
Hurwitz E; Burowski D; Kashi R; Hollander N; Haimovich J
Int J Cancer; 1986 May; 37(5):739-45. PubMed ID: 3486160
[TBL] [Abstract][Full Text] [Related]
11. Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication.
Heiger-Bernays WJ; Essigmann JM; Lippard SJ
Biochemistry; 1990 Sep; 29(36):8461-6. PubMed ID: 2174701
[TBL] [Abstract][Full Text] [Related]
12. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
Campbell MJ; Carroll W; Kon S; Thielemans K; Rothbard JB; Levy S; Levy R
J Immunol; 1987 Oct; 139(8):2825-33. PubMed ID: 3498771
[TBL] [Abstract][Full Text] [Related]
13. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.
George AJ; Tutt AL; Stevenson FK
J Immunol; 1987 Jan; 138(2):628-34. PubMed ID: 3491853
[TBL] [Abstract][Full Text] [Related]
14. Dextran-conjugated anti-IgD antibodies inhibit T cell-mediated IgE production but augment the synthesis of IgM and IgG.
Peçanha LM; Yamaguchi H; Lees A; Noelle RJ; Mond JJ; Snapper CM
J Immunol; 1993 Mar; 150(6):2160-8. PubMed ID: 7680684
[TBL] [Abstract][Full Text] [Related]
15. Treatment of lymphoid tumors with anti-idiotype antibodies.
Stevenson GT; Stevenson FK
Springer Semin Immunopathol; 1983; 6(1):99-115. PubMed ID: 6351310
[No Abstract] [Full Text] [Related]
16. Increased therapeutic efficacy of cis-platinum complexes of poly-L-glutamic acid against a murine carcinoma.
Schechter B; Wilchek M; Arnon R
Int J Cancer; 1987 Mar; 39(3):409-13. PubMed ID: 2434442
[TBL] [Abstract][Full Text] [Related]
17. Activation of human B lymphocytes by nanogram concentrations of anti-IgM-dextran conjugates.
Rehe GT; Katona IM; Brunswick M; Wahl LM; June CH; Mond JJ
Eur J Immunol; 1990 Aug; 20(8):1837-42. PubMed ID: 1698635
[TBL] [Abstract][Full Text] [Related]
18. Rejection of tumors of the B cell lineage by idiotype-vaccinated mice.
Haimovich J; Kukulansky T; Weissman B; Hollander N
Cancer Immunol Immunother; 1999 Feb; 47(6):330-6. PubMed ID: 10203063
[TBL] [Abstract][Full Text] [Related]
19. xid mice fail to express an anti-dextran immune response but carry alpha(1-3)dextran-specific lymphocytes in their potential repertoire.
Selinka HC; Bösing-Schneider R
Eur J Immunol; 1988 Nov; 18(11):1727-32. PubMed ID: 2462500
[TBL] [Abstract][Full Text] [Related]
20. Use of anti-idiotypic antibody-drug conjugates to treat experimental murine B-cell tumors.
Hurwitz E; Haimovich J
Methods Enzymol; 1989; 178():369-75. PubMed ID: 2601626
[No Abstract] [Full Text] [Related]
[Next] [New Search]
